Dr Ariella Heffernan-Marks Ovum Raise Puts Sydney Clinical Trials Into Women's Health Start-Up Focus

Sydney's founder-focused article today comes through women's health startup Ovum, after reporting on 23 June that the company has raised $4 million in seed funding and is running clinical trials with St George Hospital and the Royal Hospital for Women. The round was led by Admiralty Capital Group and included Antler, Giant Leap, Brisbane Angels and other investors. Ovum has tripled its valuation since a 2025 pre-seed round.

The founder at the centre of the story is Dr Ariella Heffernan-Marks, who founded Ovum in 2022 after her own experience with chronic migraines and feeling dismissed in healthcare settings. That origin matters because the company is not framed only as another app. Ovum is building an AI-powered women's health platform and a longitudinal dataset designed around women's health. The aim is to help users understand patterns over time and advocate for themselves in clinical settings.

For Sydney readers, the clinical-trial detail gives the story a local anchor. St George Hospital and the Royal Hospital for Women are trial partners assessing AI as a preventative health tool designed specifically for women. That moves the story beyond a funding announcement. It puts the platform into a real health-system test, where claims about user value, privacy, clinical relevance and preventative care have to meet evidence and patient experience.

Ovum has captured more than 60,000 health insights from users and facilitated more than 113,000 AI health conversations. Women aged 15 to 84 are using the app across conditions and goals including ADHD, fibromyalgia, migraines, PCOS, endometriosis, menopause, weight, diet and exercise. That range explains why the platform is trying to move beyond a narrow fertility or cycle-tracking frame.

The founder story is strong because it sits at the intersection of lived experience, medical training, data and startup execution. Many health startups struggle because the problem is real but the pathway to trust is hard. Users are being asked to record intimate health information, clinicians need to see value rather than noise, and investors want evidence that the business can grow responsibly. A founder in this field has to manage all three pressures at once.

Privacy is central. Heffernan-Marks has said Ovum will never sell user data or use it in ways users have not agreed to. A large percentage of users have opted in to contribute anonymised data for research, and all data for future clinical-research use would remain anonymised and consensual. Those commitments are important, but the public test will be how clearly the company maintains consent, transparency and security as the dataset grows.

The funding itself is also a market signal. Women's health has often been under-researched and underfunded. A raise of this size does not solve that structural problem, but it suggests investors are seeing commercial and clinical value in tools built around women's experience rather than treating it as a niche. The platform's partnerships with Medibank, Fernwood Fitness, Sweat, Menopause Friendly Australia and Australian Red Cross Lifeblood also show that the company is seeking channels beyond direct app users.

For Sydney and Surrounds, the next thing to watch is not just whether Ovum grows. It is whether local clinical trials show meaningful, measurable benefit: better symptom documentation, better preparation for appointments, earlier pattern recognition and more useful conversations between patients and health professionals. A founder story becomes a local-life story when the product being built could change how people navigate hospitals, clinics and their own health records.